CE Certificates and FDA 510(k)/PMA: Evidence Hierarchy in UAE Filings

1. Key takeaways

The EDE marketing authorization service page states that quality conformity or marketing authorization documents may be submitted according to the device class, including EC certificates, 510(k) clearances and PMA approvals, and it separately requires the EC declaration of conformity. Our judgment is that these documents sit at the tier of reference-country evidence in a UAE filing: they support the compliance assessment under Article 6(1)(c), but they cannot replace the other items of Article 6. Applicant eligibility (item a), the GMP certificate (item f) and labelling and instructions for use (item g) each carry independent evidence requirements, and a deficiency in any one of them leads to rejection regardless of how thick the reference-country evidence is.

• EC certificates, 510(k) clearances and PMA approvals are submitted according to the device class and function as reference-country evidence supporting the Article 6(1)(c) assessment.
• These documents do not replace the remaining items of Article 6: applicant eligibility, a valid GMP certificate and compliant labelling each have their own evidence requirements.
• The EC declaration of conformity is an independent document required by the EDE service page and cannot be substituted by the certificate.
• The evidentiary weight of the three document types increases stepwise, and for Class III and IV devices the service page still requires safety and effectiveness data.

2. Legal basis

The evidentiary hierarchy for CE and FDA documents in UAE filings rests on Article 6 of Federal Decree-Law No. 38/2024 and on the EDE service page for the issuance of a medical device marketing authorization, summarised below.

3. Expert insights

Insight 1: The three document types sit at different tiers, and the direction of reinforcement differs accordingly. An EC certificate shows that a conformity route has already been walked through a mature system; a 510(k) shows a determination of substantial equivalence to a product already on the market; a PMA provides an independent review conclusion on safety and effectiveness. The depth of the three increases stepwise: the conclusion of a 510(k) stops at equivalence. For Class III and IV products, the EDE service page still requires safety and effectiveness data, and a 510(k) clearance on its own is not sufficient to support a high-risk filing. We therefore work backwards from the product class to determine which evidence tier must be added, rather than operating on the assumption that any certificate in hand should simply be filed.

Insight 2: The EC declaration of conformity is an independent document and cannot be substituted for the certificate, or the other way around. The EDE service page lists the EC declaration of conformity as a separate required document, which tells us that the reviewer wants to see the manufacturer’s own declaration of conformity text, including the applicable directives or regulations, the product identification and the signing entity. In our verification work, inconsistencies between the model ranges and signing entities of the certificate and the declaration are among the most frequent causes of a document supplementation request.

Insight 3: Reference-country evidence and the Article 22 entity arrangements must both be established at the same time. CE or FDA documents solve the product side of the question. Once the product enters the UAE, Article 22 requires at least 2 importers, at least 1 distributor and 1 lead responsible entity, and each entity must actually carry out imports in the year concerned. A manufacturer holding a CE certificate who carries over a domestic arrangement in which a single agent handles everything will hit obstacles at the operationalisation stage after the certificate is granted; this is one of the first items we schedule in project planning.

4. Practical recommendations

• Determine the evidence tier by product class: for lower-risk products rely primarily on the EC certificate and declaration of conformity; for higher-risk products add safety and effectiveness data.
• Before submission, compare the consistency of the CE certificate, the EC declaration of conformity and the models to be filed, including specifications, accessories and software versions.
• For Class III and above products whose only reference evidence is a 510(k), prepare submittable versions of the clinical and performance data in advance.
• Prepare the GMP certificate separately and confirm that the issuing body is one of the three recognised sources: EDE, the competent authority of the country of origin, or a reference authority recognised by EDE.
• Prepare labelling and instructions for use in Arabic or English according to the EDE labelling guidance, and proofread the intended purpose wording in parallel with the reference-country documents.
• Chinese manufacturers holding only an NMPA registration certificate should assess reinforcement paths separately under the reliance framework, rather than applying the CE filing template directly.

5. Verification checklist

• □ The type of reference-country document to be submitted (EC/510(k)/PMA) has been confirmed according to the classification.
• □ The CE certificate, the EC declaration of conformity and the filed models, specifications and accessory ranges are consistent.
• □ The reference-country documents are in valid status at submission, with no suspension, withdrawal or narrowing of scope.
• □ The safety and effectiveness data for Class III and IV products have been organised into a submittable version.
• □ The issuing body of the GMP certificate is one of the three sources listed in Article 6(1)(f).
• □ The labelling and instructions for use conform to the EDE labelling guidance and match the intended purpose wording in the reference-country documents.

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages MOHAP registration applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com